-
2025 ASCO: Highlights of Lung Cancer Research
The annual meeting of the American Society of Clinical Oncology (ASCO) once again brought together nearly 50,000 members of the oncology community. From May 30 – June 2, researchers, oncologists, and...
IN THE SPOTLIGHT
-
Understanding DTPCs: A Path to Ending Drug Resistance in Lung Cancer
When a person is treated for advanced-stage lung cancer, tumors will often shrink, and their symptoms may subside. An effective treatment will kill many tumor cells, but there are... -
New ADC Treatment Approved for Advanced EGFR+ NSCLC
On June 23, 2025, the US Food and Drug Administration (FDA) announced the approval of datopotamab deruxtecan-dlnk (Datroway® or Dato-DXd) to treat patients with locally advanced or... -
Sharing Experiences With EGFR Lung Cancer: A Tool Shaped by Patients and Caregivers
Why did we build a tool to visualize data collected from patients and caregivers? Community members provide data but too often never see how their data was used. Research data is... -
Surviving LMD: Michelle Never Settled for “No”
Michelle knew what was wrong. She knew the headaches, regular vomiting, ear popping, and “whooshing” sounds in her head were all signs of leptomeningeal disease (LMD). The issue... -
Watch HOPE Summit Videos
HOPE Summit 2025 was filled with messages of hope, meeting new and hugging old friends, and of course the inspirational and informative sessions that help people live well with... -
Drug-Tolerant Persister Cells: From Biology to Treatment
Get ready for a provocative Facebook Live session that dives into the mystery of drug-tolerant persister cells (DTPCs)—those elusive cancer cells that survive chemotherapy and... -
What Are Antibody-Drug Conjugates and How Do They Treat Lung Cancer?
Historically, approaches to treating lung cancer included surgery, radiation, and chemotherapy. The past decade ushered in a new era of treatments with targeted therapy and... -
Integrative Oncology and Lung Cancer: Adding Complementary Therapy
What Is Integrative Oncology? Integrative oncology is the use of complementary therapies alongside conventional lung cancer treatments like chemotherapy, targeted therapy, surgery... -
EGFR Virtual Meetup
EGFR patients/survivors - Join us the 1st Wednesday of every month to connect with others who share common experiences and build your community.
HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy |
HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy |
Dizal's Zegfrovy lung cancer treatment gains FDA approval, targeting EGFR mutation
Dizal's Zegfrovy gains FDA approval for EGFR exon 20 lung cancer treatment
AKT/mTOR as a targetable hub to overcome multimodal resistance to EGFR inhibitors in oesophageal squamous cell carcinoma
AKT/mTOR as a targetable hub to overcome multimodal resistance to EGFR inhibitors in oesophageal squamous cell carcinoma
2025 ASCO: Highlights of Lung Cancer Research
2025 ASCO: Highlights of Lung Cancer Research
The annual meeting of the American Society of Clinical Oncology (ASCO) once again brought together nearly 50,000 members of the oncology community. From May 30 – June 2, researchers, oncologists, and patient advocates had first-hand access to the latest cancer research news. The theme for the 2025 ASCO conference was “Driving Knowledge to Action: Building a Better Future.” This theme was represented through several presentations during the conference that showcased how the cancer…
Investigational Oral EGFR Inhibitor Shows Promising Efficacy in Pretreated NSCLC
Dizal's ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Dizal's ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Dizal's ZEGFROVY®? (Sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Dizal's ZEGFROVY®? (Sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Dizal's ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Dizal's ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Discovery and molecular characterization of a potent thiazolyl-pyrazole hybrid targeting EGFR for breast cancer therapy
Discovery and molecular characterization of a potent thiazolyl-pyrazole hybrid targeting EGFR for breast cancer therapy
Sunvozertinib Wins Approval for EGFR-Mutated NSCLC
Understanding DTPCs: A Path to Ending Drug Resistance in Lung Cancer
Understanding DTPCs: A Path to Ending Drug Resistance in Lung Cancer
When a person is treated for advanced-stage lung cancer, tumors will often shrink, and their symptoms may subside. An effective treatment will kill many tumor cells, but there are usually some cells (called drug-tolerant persister cells, or DTPCs) left behind. If these cancer cells survive treatment, they will eventually begin to grow again.Researchers have been making progress in understanding how DTPCs grow and, importantly, how that growth can be stopped. As we learn more about these cells,…
New ADC Treatment Approved for Advanced EGFR+ NSCLC
New ADC Treatment Approved for Advanced EGFR+ NSCLC
On June 23, 2025, the US Food and Drug Administration (FDA) announced the approval of datopotamab deruxtecan-dlnk (Datroway® or Dato-DXd) to treat patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with mutations in the EGFR (epidermal growth factor receptor) gene. This approval is for patients who have been previously treated with an EGFR-directed therapy and chemotherapy. This ADC, or antibody-drug conjugate, is designed with two key elements. One part…
Sharing Experiences With EGFR Lung Cancer: A Tool Shaped by Patients and Caregivers
Sharing Experiences With EGFR Lung Cancer: A Tool Shaped by Patients and Caregivers
Why did we build a tool to visualize data collected from patients and caregivers?Community members provide data but too often never see how their data was used. Research data is mostly published in medical journals written for researchers and scientists versus the general public. Also, medical journals require the public to pay for access.We used data from a study called Project PRIORITY to create this data explorer. Project PRIORITY was a partnership between the EGFR Resisters and LUNGevity…
Surviving LMD: Michelle Never Settled for “No”
Surviving LMD: Michelle Never Settled for “No”
Michelle knew what was wrong. She knew the headaches, regular vomiting, ear popping, and “whooshing” sounds in her head were all signs of leptomeningeal disease (LMD). The issue, however, is that LMD is so rare—only diagnosed in 5% of people with cancer—she had to advocate for the testing to prove it.“I called my clinic and said I needed a brain MRI because I think I have LMD. They didn’t want to schedule one, so I said, tell my doctor I’m demanding a brain MRI. I can tell him directly if I…
Watch HOPE Summit Videos
Watch HOPE Summit Videos
HOPE Summit 2025 was filled with messages of hope, meeting new and hugging old friends, and of course the inspirational and informative sessions that help people live well with lung cancer. For the first time ever, select sessions were recorded for those who weren’t able to attend, and for those who did attend to rewatch what resonated. View the entire collection here or see below for the sessions you want to watch.HOPE Summit 2025 Recorded SessionsKeynote: Breathing Beyond Boundaries…
Drug-Tolerant Persister Cells: From Biology to Treatment
Drug-Tolerant Persister Cells: From Biology to Treatment
Get ready for a provocative Facebook Live session that dives into the mystery of drug-tolerant persister cells (DTPCs)—those elusive cancer cells that survive chemotherapy and targeted therapies, often fueling cancer’s return after treatment. These sneaky survivors are present in many cancers, and while scientists are uncovering their secrets, there is still much to learn about how to target them effectively.The conversation features Jill Feldman from the EGFR Resisters and Christine Lovly, MD…
What Are Antibody-Drug Conjugates and How Do They Treat Lung Cancer?
What Are Antibody-Drug Conjugates and How Do They Treat Lung Cancer?
Historically, approaches to treating lung cancer included surgery, radiation, and chemotherapy. The past decade ushered in a new era of treatments with targeted therapy and immunotherapy. Now, we are seeing the emergence of another class of lung cancer treatments called antibody-drug conjugates (ADCs), that are a combination of targeted therapy and chemotherapy.ADCs act like a “smart chemotherapy” that aim to deliver the drug compound directly to cancer cells, reducing harm to healthy tissue.As…
Integrative Oncology and Lung Cancer: Adding Complementary Therapy
Integrative Oncology and Lung Cancer: Adding Complementary Therapy
What Is Integrative Oncology? Integrative oncology is the use of complementary therapies alongside conventional lung cancer treatments like chemotherapy, targeted therapy, surgery, or immunotherapy. Integrative oncology—also called integrative medicine—is an evidence-informed whole-body approach to health. It is often used to address symptoms and side effects caused by disease or treatment and improve overall quality of life. Specific examples of integrative oncology for lung cancer…
What Should Patients Know About Lung Cancer Surgery?
What Should Patients Know About Lung Cancer Surgery?
Surgery is a treatment option for early-stage lung cancer that involves removing all or part of a lung to treat a cancerous tumor. It is primarily an option for people with non-small cell lung cancer (NSCLC) staged at I, II, or IIIA. Surgery is rarely considered for tumors at stage IIIB or IV because those lung cancers have spread to other parts of the body. It is also rarely used to treat small cell lung cancer (SCLC) because SCLC is typically diagnosed at a later stage. Types of…
Conversations that Count: Transforming Lung Cancer Care Through Insight and Innovation
Conversations that Count: Transforming Lung Cancer Care Through Insight and Innovation
The LUNGevity Conversations that Count speaker series offers an opportunity to stay informed, engage in critical discussions, and learn from top experts revolutionizing lung cancer care for underserved populations. The series is intended for healthcare professionals, community health equity champions, and anyone interested in equitable access to healthcare. In February, we welcomed Randi Williams, PhD, MPH, of the Lombardi Comprehensive Cancer Center at Georgetown University Medical Center…
How Do We Treat Early-Stage NSCLC in 2025?
How Do We Treat Early-Stage NSCLC in 2025?
Roughly 20% of lung cancer is diagnosed as early-stage disease, and researchers have been working to improve treatment options for these patients—with significant success. Last September, as part of LUNGevity’s International Lung Cancer Survivorship Conference, we hosted a session on the progress in treating early-stage non-small cell lung cancer (NSCLC) with Dr. Jarushka Naidoo of Beaumont RCSI Cancer Centre in Ireland and Dr. Amy Moore of LUNGevity Foundation. In October,…
Laughs for Lungs: Rasheed Marshall Combines Comedy With Cancer
Laughs for Lungs: Rasheed Marshall Combines Comedy With Cancer
Rasheed Marshall understands the secondhand effects of cancer well. First his mom, Joycelyn, was diagnosed with breast cancer in 1995. It came back in 2015 and eventually metastasized (spread) to her lungs. Soon after, his brother-in-law Romain was diagnosed with brain cancer. They both passed away the same week. “It was tough for the entire family when we learned mom’s cancer came back. She didn’t want to go through treatment again—which is why she didn’t tell us about it right away—so…
Staying Safe From Smoke, Pollution, and Dangerous Air Quality
Staying Safe From Smoke, Pollution, and Dangerous Air Quality
On the West Coast, wildfires are taking human lives and destroying homes. On the East Coast, the devastating results of Hurricane Helene are leading to illegal open burning of debris and trash. Thousands of miles separate these fires, but the results are the same—dangerous particles are entering the air we breathe. LUNGevity spoke with Angela Hopper, an 11-year lung cancer survivor who spent 30 years working as an air quality specialist at the North Carolina Department of Environmental…
Have You Heard About Cancer Cachexia?
Have You Heard About Cancer Cachexia?
Cachexia is a complex condition that causes severe muscle and weight loss, physical inactivity, and metabolic disruptions such as fatigue, nausea, and loss of concentration. It's estimated that 50% of individuals with lung cancer experience cachexia at some point.Learn more about cachexia and how to recognize the symptoms.
Conversations that Count: Understanding the Complexities of Race and Health
Conversations that Count: Understanding the Complexities of Race and Health
The LUNGevity Conversations that Count speaker series offers an opportunity to stay informed, engage in critical discussions, and learn from top experts revolutionizing lung cancer care for underserved populations. The series is intended for healthcare professionals, community health equity champions, and anyone interested in equitable access to healthcare. In January, we welcomed Matthew McCurdy, MPH, co-founder and executive director of BLKHLTH, to speak on the complexities of race and…
Real-World Examples of Patient Involvement in Designing Clinical Trials
Real-World Examples of Patient Involvement in Designing Clinical Trials
Read time: 2 minutes.Here we present the final video in our three-part series about how patients and researchers can work together to develop clinical trials. In the video below, LUNGevity again partnered with Rising Tide for Clinical Cancer Research to illustrate the power of having patients contribute to the research process. We use a real-world example to learn about patient-researcher collaborations through the POSITIVE study, a breast cancer-focused clinical trial. You can…
Developing Clinical Trials that Account for the Realities of Patient Life
Developing Clinical Trials that Account for the Realities of Patient Life
Read time: 2 minutes. We are pleased to continue our three-part series about how patients and researchers can work together to develop clinical trials. In this second video, LUNGevity again partnered with Rising Tide for Clinical Cancer Research to show how researchers and patient advocates can be empowered with tools to create clinical trials that resonate with patients and address the key issues they care about. If you missed the first video, How Can Patients…
Our Dream Was to Start a Family, but Lung Cancer Changed Everything
Our Dream Was to Start a Family, but Lung Cancer Changed Everything
Read time: 6 minutes. After a few unimpressive encounters I experienced in real life, I tentatively returned to the Match dating app. That’s where I stumbled upon a very sweet, kind-hearted, nerdy, and compassionate man. Then I met Nate (Ha! Just joking). It was Nate. We bonded so quickly during which we identified our life goals. One goal was to have a family. Yes, we did the whole “let’s get ready” experience. We invested in a new SUV. We were eyeing new housing…
The 5 Most Popular Lung Cancer Blogs From 2024
The 5 Most Popular Lung Cancer Blogs From 2024
Read time: 3 minutes. Throughout 2024 we published blogs sharing scientific meeting recaps, educational content, personal stories, treatment news, and so much more. Below are the most popular articles we published in 2024. If you’re looking for survivor features and personal stories, you can see all the lung cancer survivors we highlighted in 2024 right here. 2024 ASCO: Highlights of Lung Cancer Research In June, we recapped the annual American Society of…